CONTINUE TO SITE

OR WAIT null SECS

COVID-19 Update Analytics Dosage Forms Drug Development Manufacturing Outsourcing Quality Systems

COVID-19 UpdateAnalyticsDosage FormsDrug DevelopmentManufacturingOutsourcingQuality Systems

View More Analytical Method Development APIs Aseptic Processing Biologic Drugs Drug Delivery Equipment Excipients Formulation Packaging Process Control/PAT Process Development QA/QC Regulatory Action Supply Chain

Analytical Method DevelopmentAPIsAseptic ProcessingBiologic DrugsDrug DeliveryEquipmentExcipientsFormulationPackagingProcess Control/PATProcess DevelopmentQA/QCRegulatory ActionSupply Chain

News

All News Top News Industry News Bio/Pharma News Supplier News News from Europe Events

All NewsTop NewsIndustry NewsBio/Pharma NewsSupplier NewsNews from EuropeEvents

Publications

All Publications PharmTech PharmTech Europe

All PublicationsPharmTechPharmTech Europe

Resources

Front & Center Pharma Insights Sponsored eBooks Sponsored Podcasts Sponsored Videos Whitepapers

Front & CenterPharma InsightsSponsored eBooksSponsored PodcastsSponsored VideosWhitepapers

Webcasts Marketplace

Enewsletters Magazine North America Magazine Europe

EnewslettersMagazine North AmericaMagazine Europe

About Us
Advertise
Contact Us
Editorial Info
Editorial Contacts
Editorial Advisory Board
Do Not Sell My Personal Information
Privacy Policy
Terms and Conditions

Spotlight

COVID-19 Update
Analytics
Dosage Forms
Drug Development
Manufacturing
Outsourcing
Quality Systems

TopicSee All >

Analytical Method Development
APIs
Aseptic Processing
Biologic Drugs
Drug Delivery
Equipment
Excipients
Formulation
Packaging
Process Control/PAT
Process Development
QA/QC
Regulatory Action
Supply Chain

About Us
Advertise
Contact Us
Editorial Info
Editorial Contacts
Editorial Advisory Board
Do Not Sell My Personal Information
Privacy Policy
Terms and Conditions

Outsourcing

home

Developing the Best Formulation Partnership

Collaborative partnerships can foster success in formulation development projects.

Pharma Services Sector Poised for Continued Growth

The CRO market will see consolidation by financial buyers and larger CRO players.

Fujifilm Grows Lab Space at North Carolina Facility

January 13, 2022

Fujifilm Diosynth Biotechnologies' 89,000 square-foot expansion of its BioProcess Innovation Center in Research Triangle Park, N.C., will double its capacity to support process characterization.

Merck KGaA Acquires CDMO Exelead

January 11, 2022

The agreeement will add to Merck KGaA’s LNP and mRNA capabilities.

Insightful Science Completes Acquisition of Protein Metrics

January 07, 2022

The acquisition of Protein Metrics expands Insightful Science’s R&D solutions to include proteomics.

Piramal Pharma Invests Minority Stake in India-Based CDMO, Yapan Bio

January 05, 2022

With this investment into Yapan Bio, Piramal Pharma adds new technologies and capabilities in large molecules, including vaccines and gene therapies, to its global offering.

Without a Particle of Doubt

January 05, 2022

Particle analysis provides assurances of the quality and performance of the final dosage form in pharmaceutical development.

The Need for Speed: How Operation Warp Speed Shifted the Pharma Industry

January 03, 2022

A new focus on speed to market creates challenges for facility design and construction.

Outsourcing’s Race Toward Novelty

January 02, 2022

Recent developments in the outsourcing industry include a focus on early development services, biosimilar production, and RNA technology.

FUJIFILM Irvine Scientific Opens New European Manufacturing Facility

December 16, 2021

FUJIFILM Irvine Scientific’s new manufacturing facility in Tilburg, the Netherlands, is now fully operational.

FUJIFILM Diosynth Biotechnologies to Create Major Biopharma Manufacturing Site in United Kingdom

December 16, 2021

FUJIFILM Diosynth Biotechnologies plans to invest £400 million (US$528 million) to expand its Billingham, Teeside facility in the United Kingdom.

Lonza and Bioqube Ventures Form Agreement for Future Development and Manufacture of Biologics and Small Molecules

December 09, 2021

Lonza has signed a five-year services agreement to provide for the development and manufacturing of biologics and small molecules for portfolio companies owned by Bioqube Ventures.